SCOTTSDALE, AZ USA (UroToday.com) - This was a retrospective analysis of all patients who received BTA injections for refractory OAB between 2010 and 2014. Refractory OAB are those patients who have failed behavioral therapy, anticholinergics, and beta-3 agonists, first- and second-line therapies.
Patients excluded (n=12) were those missing medication histories or those who had a diagnosis of neurogenic detrusor overactivity. The number of second-line therapies prescribed prior to the first injection were collected and included an average of 2.5 (range 1-6) medications that were prescribed prior to initiation of BTA therapy. BTA injections were given to 93 consecutive patients (female= 66%, male=34%, mean age was 72.5). An average of 2.5 medications were prescribed prior to BTA with an increase in the number of medications prescribed prior to injection between January 2010 and September 2013, with a downward trend between January 2013 and September 2014 after FDA approval of BTA.
This data was not statistically significant, but the authors felt that this may reflect a tendency on the part of the physicians to avoid anticholinergic cycling. However, there may be confounding factors affecting these changes, and these were not accounted for. Therefore they are not generalizable to other regions and populations.
Presented by E. Enemchukwu, N. Talreja, N. Rosenblum, B. Brucker, and V. Nitti at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Winter Meeting - February 24 - 28, 2015 - JW Marriott Camelback Inn Resort & Spa - Scottsdale, AZ USA
Reported by Diane K. Newman, DNP, FAAN, BCB-PMD, medical writer for UroToday.com.